PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me

What FDA’s record states

FDA record for the warning letter to RonanRx, Inc. dba RonanRx
FieldWhat FDA’s record statesSource
RecipientRonanRx, Inc. dba RonanRxFDA letter
LocationNot published by FDAn/a
Letter dateOct 30, 2026FDA letter
Posted by FDANov 3, 2026FDA index
Issuing officeCenter for Drug Evaluation and Research (CDER)FDA letter
SubjectFalse & Misleading Claims/Misbranded (Telehealth)FDA letter
MARCS-CMS number737905FDA letter
GLP-1 drugs namedSemaglutide, TirzepatideFDA letter
Response letterNot published by FDAFDA letter
Closeout letterNot published by FDAFDA letter
“FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.”FDA warning letter to RonanRx, Inc. dba RonanRx, Oct 30, 2026 · read the full letter on fda.gov ↗

What this is and is not. A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Source

Every field above is copied from FDA’s page for this letter, read Nov 18, 2026. The letter on fda.gov ↗ · All 164 GLP-1 warning letters